Kraig's Monster Silk pilot program ahead of schedule

The production capacity for the first two stages exceeds the Company's prior maximum capacities by a factor of four or five.

The program is designed to be the basis of the Company's large scale commercial production of its recombinant spider silks. The program is designed to run in three stages; with each successive stage launching when the previous stage's data indicates that the program is reaching, or exceeding, its benchmarks.

The current data supports the continued fast-tracking of the program, as the second phase is developing on track, surpassing the trial's initial phase in terms of capacity and success rates. The first stage continues to run ahead of expectations and is already moving to an advanced state.

"So far the pilot production program has exceeded our expectations and is confirming that our production model is fully scalable, as Phase II surpassed the program's first phase, despite the fact that it's a much larger trial," said Kraig founder and CEO, Kim Thompson. "From the beginning, this has been an ambitious program, which now appears to be rewarding our efforts. We are continuing to rapidly advance through stage two of the production program."

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc., a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry. The Company has recently launched a pilot production program as a major step toward large scale commercial production.

Kraig Biocraft Laboratories, Inc